......................................................................................................
Illustrated below is one of the clinical examples of the applicaton of blood pool contrast agent from www.bloodpoolagents.com:
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhODlhYdwZvAtr5FkwXgxqRqSg6KAjs-slzzZMyAKzMjU7RYPLyYWgMgfebNTpR3Cq5uh2D67yP79376qhEKzfgq4yEFoFKkvwpvzVMdcJ827EiJ_SbmnIsad3moMMxixul211cGtlLtak/s400/Thrombosis.002.png)
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiwIEykbUSywq5uMjB3yAQ3slt9I3i12IKZONazLviMppMtVJclzuHkeTNT_z0XFrAKdRQSQCVULZvIDzhBoGGfswQFRQTibRj6lsTvBLkCDcolncBlQQW9aGyzHXKrpLtTKKaq5qGOB_M/s400/Blood+Pool+Agent.003.png)
(Click on image to enlarge)
More information on Blood Pool Agents.
Tags: Ablavar, Gadofosveset trisodium, Gd, MRA, AIOD, PVD, blood pool contrast agent, aneurysm spurium, thrombosis
Reference:
Goyen M et al. MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325.Radiology. 2005;236(3):825-833.
Goyen M et al. MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325.Radiology. 2005;236(3):825-833.
Rapp JH et al. Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography—multicenter comparative phase III study. Radiology. 2005;236(1):71-78.
Perreault P et al. MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial.Radiology. 2003;229(3):811-820.